Glucagon in eleven dogs with insulinoma

The illness being treated

An insulinoma is an insulin-producing tumour. The 2020 glucagon report describes 11 dogs with insulinoma who received treatment in hospital for dangerously low blood sugar. Glucagon is a hormone that raises blood sugar.

This is a more immediate clinical setting than the healthy-beagle experiments. The illness in those dogs and the specific treatment purpose are why this report matters to me. That makes the report relevant to a narrow question about hospital care.

Looking back at treatment

The study was retrospective and descriptive: the investigators looked back at treated cases. There was no comparison group. The authors concluded that glucagon therapy was effective in managing low blood sugar in these insulinoma cases.

I take their conclusion seriously within the limits of those cases. Eleven dogs without a comparison group leave me reluctant to make a general rule. It records veterinary treatment of a dangerous condition; it gives an owner no basis for attempting that treatment at home.

Glucagon's animal-drug record

The animal-drug database check recorded on September 30, 2026 found no FDA animal application for glucagon. The treatment report and the regulatory record answer separate questions: one describes the cases, while the other records the animal-drug status checked on that date.

I would bring this paper into a discussion with a veterinarian about insulinoma, with the hospital setting and small retrospective design still attached. A claim about peptides for all dogs would lose the very particulars that make this report worth considering.

The veterinarian page explains the conditions around use of an approved medicine outside its label.